6272 related articles for article (PubMed ID: 3498854)
41. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
42. Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity.
Derbyshire EJ; Wawrzynczak EJ
Br J Cancer Suppl; 1991 Jun; 14():74-7. PubMed ID: 1645578
[TBL] [Abstract][Full Text] [Related]
43. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
44. Human melanoma cell lines showing striking inherent differences in sensitivity to immunotoxins containing holotoxins.
Godal A; Fodstad O; Morgan AC; Pihl A
J Natl Cancer Inst; 1986 Dec; 77(6):1247-53. PubMed ID: 3491924
[TBL] [Abstract][Full Text] [Related]
45. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
46. Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells.
He D; Yang H; Lin Q; Huang H
Int J Biochem Cell Biol; 2005 Jan; 37(1):192-205. PubMed ID: 15381161
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
Raso V; Ritz J; Basala M; Schlossman SF
Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
[TBL] [Abstract][Full Text] [Related]
48. Targeted anti-tumor agents and their cytotoxicity on gastric cancer cells in vitro.
Li S; Zhang XY; Chen XT; Fan DM; Tan LS; Pan HZ; Huang LQ
Chin Med J (Engl); 1990 May; 103(5):376-9. PubMed ID: 2118053
[TBL] [Abstract][Full Text] [Related]
49. Selective cytotoxic effects of immunotoxin--monoclonal anti-AFP-abrin-A chain conjugate on several human hepatoma cell lines.
Chow LP; Chang KH; Lin JY
Biochem Int; 1990 Oct; 22(1):95-102. PubMed ID: 1704234
[TBL] [Abstract][Full Text] [Related]
50. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
51. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
52. Transcriptionally targeted in vivo gene therapy for carcinoembrionic antigen-producing adenocarcinoma.
Konishi F; Maeda H; Yamanishi Y; Hiyama K; Ishioka S; Yamakido M
Hiroshima J Med Sci; 1999 Sep; 48(3):79-89. PubMed ID: 10598410
[TBL] [Abstract][Full Text] [Related]
53. Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates.
Leonard JE; Wang QC; Kaplan NO; Royston I
Cancer Res; 1985 Nov; 45(11 Pt 1):5263-9. PubMed ID: 3876881
[TBL] [Abstract][Full Text] [Related]
54. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
55. Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines.
Embleton MJ; Byers VS; Lee HM; Scannon P; Blackhall NW; Baldwin RW
Cancer Res; 1986 Nov; 46(11):5524-8. PubMed ID: 3489523
[TBL] [Abstract][Full Text] [Related]
56. Immunotoxin preparation and testing in vitro.
Frankel AE; Welsh PC; Withers DI; Schlossman DM
Targeted Diagn Ther; 1988; 1():225-44. PubMed ID: 2979057
[No Abstract] [Full Text] [Related]
57. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
[TBL] [Abstract][Full Text] [Related]
58. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors.
Martell LA; Agrawal A; Ross DA; Muraszko KM
Cancer Res; 1993 Mar; 53(6):1348-53. PubMed ID: 8443815
[TBL] [Abstract][Full Text] [Related]
60. Selective inhibition of growing pigment epithelial cells by a receptor-directed immunotoxin.
Davis AA; Whidby DE; Privette T; Houston LL; Hunt RC
Invest Ophthalmol Vis Sci; 1990 Dec; 31(12):2514-9. PubMed ID: 2265991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
